TrianglePMD-026 (NCT07379125)
PMD-026 trial for Myelofibrosis (NCT07379125). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with myelofibrosis, a bone marrow cancer.
The idea: PMD-026 is a pill taken every twelve hours that blocks RSK1, a protein called ribosomal protein S6 kinase A1. Two dose levels are tested, then more patients are added at the chosen dose.
The study looks for the recommended dose, then at how well it works.
This phase 1 study plans 18 patients. At Washington University School of Medicine in St. Louis, Amy Zhou leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.